CLOSEOUT LETTER
Health King Enterprises & Balanceuticals Group, Inc.
- Recipient:
- Health King Enterprises & Balanceuticals Group, Inc.
United States
- Issuing Office:
United States
| Food and Drug Administration |
| Chicago District 550 West Jackson Blvd., 15th Floor Chicago, Illinois 60661 Telephone: 312-353-5863 |
Department of Health and Human Services
June 24, 2014
Mr. Xingwu Liu
President
Health King Enterprises & Balanceuticals Group, Inc.
238 West 31st Street
Chicago, Illinois 60616
Dear Mr. Liu:
The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter, CHI-14-13 dated July 11, 2013. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Scott J. MacIntire
District Director
cc: Mr. James Liu, General Manager